N-(5-(5-amino-6-chloropyridin-3-yl)-4-methylthiazol-2-yl)acetamide | 887308-20-5

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: N-(5-(5-amino-6-chloropyridin-3-yl)-4-methylthiazol-2-yl)acetamide
• 英文别名: N-[5-(5-amino-6-chloropyridin-3-yl)-4-methyl-1,3-thiazol-2-yl]acetamide
• CAS: 887308-20-5
• 化学式: C₁₁H₁₁ClN₄OS
• 分子量: 282.754
• InChiKey: AYECKLYDYDHIHM-UHFFFAOYSA-N

物化性质

• 密度：
  1.455±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  109
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  N-(5-(5-amino-6-chloropyridin-3-yl)-4-methylthiazol-2-yl)acetamide 在 吡啶 、 盐酸 、 N,N-二异丙基乙胺 、 Methanaminium,N-[(dimethylamino)(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)methylene]-N-methyl-, hexafluorophosphate(1-) 作用下， 以 乙醇 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 21.0h， 生成 tert-butyl (1-((5-(6-chloro-5-(phenylsulfonamido)pyridin-3-yl)-4-methylthiazol-2-yl)amino)-2-methyl-1-oxopropan-2-yl)carbamate
  参考文献：
  名称：

  Discovery of (S)-2-amino-N-(5-(6-chloro-5-(3-methylphenylsulfonamido)pyridin-3-yl)-4-methylthiazol-2-yl)-3-methylbutanamide (CHMFL-PI3KD-317) as a potent and selective phosphoinositide 3-kinase delta (PI3Kδ) inhibitor

  摘要：

  PI3K delta, which is mainly expressed in leukocytes, plays a critical role in B-cell receptor mediated signaling pathway and has been extensively studied as a drug discovery target for B cell malignances such as AML, CLL etc. In this manuscript, we report the discovery, SAR optimization and pharmacological evaluation of a novel series of aminothiazole-pyridine containing PI3K delta inhibitors. Among them compound 151 (CHMFL-PI3K delta-317) displays an IC50 of 6 nM against PI3K delta in the ADP-Glo biochemical assays. It also exhibits over 10-1500 fold selectivity over other class I, II and III PIKK family isoforms. In addition, in the cellular context, 15i can selectively and potently inhibit PI3K delta mediated phosphorylation of Akt T308 but not PI3K delta, beta, gamma mediated Akt phosphorylation. 15i also exhibits an excellent selectivity profile in the protein kinases including 468 kinases/mutants at the concentration of 1 mu M. 15i has acceptable pharmacokinetic properties and can dose-dependently inhibit the tumor growth of AML cell line MOLM14 inoculated xenograft mouse model. The high selectivity and potency makes 15i a potential valuable addition to the current PI3K delta armory. (C) 2018 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2018.07.036
• 作为产物：
  描述：

  5-溴-2-氯-3-硝基吡啶 在 palladium diacetate cesium fluoride 、 lithium chloride 作用下， 以 二甲基亚砜 为溶剂， 反应 23.17h， 生成 N-(5-(5-amino-6-chloropyridin-3-yl)-4-methylthiazol-2-yl)acetamide
  参考文献：
  名称：

  WO2007/129044

  摘要：

  公开号：

文献信息

• Potent, selective small molecule inhibitors of type III phosphatidylinositol-4-kinase α- but not β-inhibit the phosphatidylinositol signaling cascade and cancer cell proliferation
  作者：Michael J. Waring、David M. Andrews、Paul F. Faulder、Vikki Flemington、Jennifer C. McKelvie、Sarita Maman、Marian Preston、Piotr Raubo、Graeme R. Robb、Karen Roberts、Rachel Rowlinson、James M. Smith、Martin E. Swarbrick、Iris Treinies、Jon J. G. Winter、Robert J. Wood

  DOI：10.1039/c3cc48391f

  日期：——

  Two series of inhibitors of type III phosphatidylinositol-4-kinase were identified by high throughput screening and optimised to derive probe compounds that independently and selectively inhibit the alpha- and the beta-isoforms with no significant activity towards related kinases in the pathway. In a cellular environment, inhibition of the alpha- but not the beta-subtype led to a reduction in phos

  通过高通量筛选鉴定了两个系列的III型磷脂酰肌醇4-激酶抑制剂，并对其进行了优化，以衍生出能够独立，选择性地抑制α-和β-同工型而对路径中相关激酶没有明显活性的探针化合物。在细胞环境中，抑制α-亚型而不抑制β-亚型会导致4-磷酸磷脂酰肌醇和-4,5-磷酸二磷酸肌醇浓度的降低，从而导致肌醇-1-磷酸形成的抑制和增殖的抑制。一组癌细胞系。
• 5-Heteroaryl Thiazoles And Their Use As PI3K Inhibitors
  申请人：Bengtsson Malena

  公开号：US20080132502A1

  公开（公告）日：2008-06-05

  The invention provides thiazole derivatives of formula (I), or pharmaceutically acceptable salts thereof in which Ring A, R 1 , R 2 and R 3 are as defined in the specification; a processes for their preparation; pharmaceutical compositions containing them; and their use in therapy, for example in the treatment of disease mediated by a PI3K enzyme and/or a mTOR kinase.

  本发明提供式(I)的噻唑衍生物或其药学上可接受的盐，其中环A、R1、R2和R3如说明书中所定义；一种制备它们的方法；含有它们的制药组合物；以及它们在治疗中的用途，例如用于治疗由PI3K酶和/或mTOR激酶介导的疾病。
• THIAZOLE DERIVATIVES AND THEIR USE AS ANTI-TUMOUR AGENTS
  申请人：Arnould Jean-Claude (Retired)

  公开号：US20090076009A1

  公开（公告）日：2009-03-19

  The invention concerns thiazole derivatives of Formula I or pharmaceutically-acceptable salts thereof, wherein each of R, Ring A, m, R 1 , R 2 and R 3 has any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in therapy, for example in the treatment of disease mediated by a PI3K enzyme and/or a mTOR kinase.

  本发明涉及式I的噻唑衍生物或其药学上可接受的盐，其中R、环A、m、R1、R2和R3中的每一个都具有前述描述中定义的任何含义；其制备方法、包含它们的制药组合物以及它们在治疗中的用途，例如用于治疗由PI3K酶和/或mTOR激酶介导的疾病。
• 5-heteroaryl thiazoles and their use as PI3K inhibitors
  申请人：AstraZeneca AB

  公开号：US07868188B2

  公开（公告）日：2011-01-11

  The invention provides thiazole derivatives of formula (I), or pharmaceutically acceptable salts thereof in which Ring A, R1, R2 and R3 are as defined in the specification; a processes for their preparation; pharmaceutical compositions containing them; and their use in therapy, for example in the treatment of disease mediated by a PI3K enzyme and/or a mTOR kinase.

  本发明提供了式(I)的噻唑衍生物或其药学上可接受的盐，其中环A、R1、R2和R3如规范中所定义；它们的制备方法；含有它们的药物组合物；以及它们在治疗中的用途，例如用于治疗由PI3K酶和/或mTOR激酶介导的疾病。
• [EN] NEW PI3K KINASE INHIBITOR<br/>[FR] NOUVEL INHIBITEUR DE LA KINASE PI3K<br/>[ZH] 一种新型的PI3K激酶抑制剂
  申请人：HEFEI INST PHYSICAL SCI CAS

  公开号：WO2016101553A1

  公开（公告）日：2016-06-30

  本发明涉及一种PI3K激酶抑制剂，其包括式I的化合物或其药学可接受的盐、溶剂化物、酯、酸、代谢物或前药，其中Y、W、Z、R1、R2、R3、R4如说明书所定义。本发明还涉及包括式I化合物的药物组合物及其在制备用于治疗由PI3K激酶活化介导的病症的药物中的用途。